From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors.
Jautelat
Rolf
R
Medicinal Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany. rolf.jautelat@schering.de
Brumby
Thomas
T
Schäfer
Martina
M
Briem
Hans
H
Eisenbrand
Gerhard
G
Schwahn
Stefan
S
Krüger
Martin
M
Lücking
Ulrich
U
Prien
Olaf
O
Siemeister
Gerhard
G
D000255:Adenosine Triphosphate / Q000494:pharmacology; D001665:Binding Sites; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D004396:Coloring Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D050759:Cyclin-Dependent Kinase Inhibitor p21; D007211:Indoles / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D008958:Models, Molecular; D015394:Molecular Structure; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D017434:Protein Structure, Tertiary; D012995:Solubility; D013449:Sulfonamides / Q000737:chemistry
D018797:Cell Cycle Proteins; D004396:Coloring Agents; D050759:Cyclin-Dependent Kinase Inhibitor p21; D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000255:Adenosine Triphosphate; C027185:indirubin